Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Opinion and Comment
Nature Biotechnology 27, 601–602 (1 July 2009) | doi:10.1038/nbt0709-601
More eyeballs on AERS
&
Abstract
To the Editor: Your recent editorial 'Making a difference' advocated “the immediate overhaul of the FDA's antiquated Adverse Event Reporting System (AERS)” for drugs. As described, the modern version of AERS is thought to be the largest database of its kind, consisting of |[sim]|3 million reports of adverse drug reactions and has the potential to serve as a useful data source in pharmacovigilance efforts.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
